HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
orilanolimab
FcRn-blocking monoclonal antibody
Also Known As:
SYNT001
Networked:
1
relevant articles (
1
outcomes,
1
trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Amino Acids, Peptides, and Proteins: 1
Proteins: 484843
Blood Proteins: 12459
Serum Globulins: 553
Immunoglobulins: 30480
Antibodies: 133716
Monoclonal Antibodies: 56412
Humanized Monoclonal Antibodies: 217
orilanolimab: 1
Immunoproteins: 43
Immunoglobulins: 30480
Antibodies: 133716
Monoclonal Antibodies: 56412
Humanized Monoclonal Antibodies: 217
orilanolimab: 1
Globulins: 3062
Serum Globulins: 553
Immunoglobulins: 30480
Antibodies: 133716
Monoclonal Antibodies: 56412
Humanized Monoclonal Antibodies: 217
orilanolimab: 1
Experts
1.
Murrell, Dedee F
: 1 article (12/2021)
2.
Zeng, Faith A P
: 1 article (12/2021)
Related Diseases
1.
Pemphigus (Pemphigus Vulgaris)
12/01/2021 - "
FcRn blockers such as SYNT001 have shown positive results in preliminary phase 2 clinical trials for treatment of human pemphigus; further trials are required.
"
12/01/2021 - "
Les bloqueurs FcRn tels que SYNT001 ont montré des résultats positifs dans les essais préliminaires cliniques de phase 2 pour le traitement du pemphigus de l’homme ; d’autres études sont nécessaires.
"